SUNPHARMA's weekly performance was disappointing, with a return of -0.69%, indicating a decline in stock value. The stock's volatility was relatively high at 19.52%, suggesting significant price fluctuations. Compared to its peers, SUNPHARMA underperformed DRREDDY but outperformed DIVISLAB and HINDUNILVR. The stock's Sharpe Ratio of -0.18 and Max Drawdown of -1.28% indicate a relatively high level of risk.

[Volatility: 19.52%]